Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
173 results about "Nitric oxide synthase" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Nitric oxide synthases (EC 1.14.13.39) (NOSs) are a family of enzymes catalyzing the production of nitric oxide (NO) from L-arginine. NO is an important cellular signaling molecule. It helps modulate vascular tone, insulin secretion, airway tone, and peristalsis, and is involved in angiogenesis and neural development. It may function as a retrograde neurotransmitter. Nitric oxide is mediated in mammals by the calcium-calmodulin controlled isoenzymes eNOS (endothelial NOS) and nNOS (neuronal NOS).
Muscle-derived cells (MDCs) for treating muscle- or bone-related injury or dysfunction
The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.
Owner:UNIVERSITY OF PITTSBURGH
Neuronal pain pathway
ActiveUS20060216339A1High activityImprove the level ofNervous disorderDipeptide ingredientsCyclasePhosphorylation
The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
3-Cyanoquinoline derivative, preparation method and medical use thereof
InactiveCN101012225AImprove function and effectOrganic active ingredientsOrganic chemistryDual inhibitorQuinoline
The invention discloses a making method of compound I and drug composition and application to treat tumour, which is 3-cyano quinoline derivant (I) as dual-inhibitor protein kinase of tyrosine and nitric oxide synthase, wherein G1, G2, G3, G4, X, Z and n are defined as instruction.
Owner:CHINA PHARM UNIV
Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase
InactiveUS6495544B2Avoid problemsAvoid tissue damageBiocideSenses disorderMedicinal chemistryHexanoic Acid Derivatives
Homoiminopiperidinyl Hexanoic Acid derivatives and pharmaceutically acceptable salts thereof useful in the inhibition of the inducible isoform of nitric oxide synthase are disclosed.
Owner:PHARMACIA CORP
Nitrosated and nitrosylated prostaglandins, compositions and methods of use
The invention describes novel nitrosated and / or nitrosylated prostaglandins, and novel compositions comprising at least one nitrosated and / or nitrosylated prostaglandin, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and / or at least one vasoactive agent. The invention also provides novel compositions comprising at least one prostaglandin and at least one S-nitrosothiol compound, and, optionally, at least one vasoactive agent. The prostaglandin is preferably a prostaglandin E1 compound, more preferably alprostadil, and the S-nitrosothiol compound is preferably S-nitrosoglutathione. The invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cerebrovascular disorders, cardiovascular disorders, benign prostatic hyperplasia (BPH), glaucoma, peptic ulcers or for inducing abortions.
Owner:NITROMED
Composition for the prevention and the treatment of helicobacter pylori infection
InactiveUS20100298244A1Decrease apoptotic damageReduce productionAntibacterial agentsBiocideSialic acidMedicine
The disclosed item is a composition comprising catechins and sialic acid to provide an effective prevention and treatment for Helicobacter Pylori infection. This composition inhibits growth of Helicobacter pylori, and can increase the antioxidant activity of gastric mucosal cells through reducing the production of O2.−, H2O2 and NO, and decreasing the expression of inducible nitric oxide synthase (iNOS) in cells. The apoptotic damage of stomach caused by Helicobacter pylori was decreased through up-regulation of autophagy to enhance the defensive ability of gastric epithelial cells toward Helicobacter pylori. Therefore the composition can be used in the treatment or prevention on damages caused by Helicobacter pylori infection.
Owner:NAT TAIWAN UNIV
Selective targeting agents for mitochondria
ActiveUS7718603B1Improve survivalOrganic active ingredientsDipeptide ingredientsDiseaseRos scavenging
The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargos which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the β-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. In a preferred embodiment, the compositions and methods may be administered therapeutically in the field to patients with profound hemorrhagic shock so that survival could be prolonged until it is feasible to obtain surgical control of the bleeding vessels. In further preferred embodiments, the composition for scavenging radicals in a mitochondria membrane includes a radical scavenging agent and a membrane active compound having a high affinity with said mitochondrial membrane and associated methods. In another embodiment, the cargo transported by mitochondrial-selective targeting agents may include an inhibitor of nitric oxide synthase (NOS) enzyme activity.
Owner:UNIVERSITY OF PITTSBURGH
Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
InactiveUS20040229920A1Improve breathabilityHigh viscosityBiocideOrganic chemistryActive agentCerebrovascular disorder
The present invention describes novel nitrosated and / or nitrosylated potassium channel activators, and novel compositions comprising at least one nitrosated and / or nitrosylated potassium channel activator, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or at least one vasoactive agent. The present invention also provides novel compositions comprising at least one potassium channel activator, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or at least one vasoactive agent. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing cardiovascular disorders, cerebrovascular disorders, hypertension, asthma, baldness, urinary incontinence, epilepsy, sleep disorders, gastrointestinal disorders, migraines, irritable bowel syndrome and sensitive skin.
Owner:GARVEY DAVID S +1
Inducible nitric oxide synthase dimerization inhibitors
InactiveUS20060116515A1Useful activityNervous disorderOrganic chemistryStructural formulaNITRIC OXIDE SYNTHASE 1
The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR4, N, NR4, S, and O; U is selected from the group consisting of CR10 and N; V is selected from the group consisting of CR4 and N; W and W′ are independently selected from the group consisting of CH2, CR7R8, NR9, O, N(O), S(O)q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.
Owner:KALYPSYS INC
Methods for Treating Cancer
InactiveUS20070219208A1Cause deathInhibit proliferation causeBiocidePeptide/protein ingredientsHMG-CoA reductaseNitric oxide formation
It is disclosed here that HMG-CoA reductase inhibitors inhibit the proliferation and cause the death of breast cancer cells by inducing the expression of inducible nitric oxide synthase (iNOS) to promote intracellular nitric oxide formation, which the inventors found to be accomplished through the inhibition of protein geranylgeranylation. The disclosure here enables a new breast cancer treatment strategy that combines the inhibition HMG-CoA reductase or protein geranylgeranylation and the promotion of nitric oxide formation by iNOS.
Owner:MCW RES FOUND INC
Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
InactiveUS7138430B2Prevention of platelet aggregation and platelet adhesionAntibacterial agentsBiocideMetaboliteAntioxidant
Owner:NICOX SA
Methods of diagnosing and treating complications of pregnancy
ActiveUS20070104707A1Increasing expression level and biological activityIncreases dephosphorylationOrganic active ingredientsDisease diagnosisDiseaseComplicated pregnancy
Disclosed herein are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using combinations of compounds that alter soluble endoglin and sF1t-1 expression levels or biological activity. Also disclosed are methods for treating a pregnancy related hypertensive disorder, such as pre-eclampsia and eclampsia, using compounds that increase endothelial nitric oxide synthase levels or biological activity.
Owner:HOSPITAL FOR SICK CHILDREN +1
Anti-inflammatory peptide separated from haliotis discus hannai abalone visceral organ and use of anti-inflammatory peptide
The present invention is used for evaluating the advantages of haliotis discus hannai. A multi-phase HPLC purification system is used to purify anti-inflammatory peptide from abalone (AAIP, abalone anti-inflammatory peptide). In tandem MS analysis, a fragmentation result shows that the amino acid sequence of the AAIP with nitrogen monoxide (NO) inhibitory activity (IC50=55.8[um]M) is Pro-Phe-Asn-Glu-Gly-Thr-Phe-Ala-Ser (1175.2Da). While the anti-inflammatory effect of RAW264.7 macrophages generated by the stimulus of the AAIP to lipopolysaccharides (LPS) is further studied, and the molecular mechanism is elaborated. The result shows that the AAIP peptide inhibits the nitrogen monoxide (NO) generation induced by the LPS through the expression of inducible nitric oxide synthase (iNOS) by a dose-dependent manner, and the gene transcription of pro-inflammatory cytokines is also obviously reduced, wherein the pro-inflammatory cytokines comprise such as interleukin (IL-1 beta), tumor necrosis factors (TNF-beta) and IL-6. In addition, the AAIP obviously inhibits phosphorylation of mitogen-activated protein kinases (MAPK), such as p-p38 and p-JNK. These results indicate that the AAIP inhibits inflammatory response induced by LPS by intercepting the MAPK pathway of the macrophages. Therefore, the AAIP can be applied to therapeutic drugs for inflammations treatment or healthcare food products.
Owner:千忠吉
Transgenic soybean GTS40-3-2 and endogenous and exogenous gene multi-nested fluorescent quantitative PCR (polymerase chain reaction) detection primer combination method
ActiveCN104450946AEasy to detectReduce demandMicrobiological testing/measurementDNA/RNA fragmentationTransgenesisMultiplex pcrs
The invention discloses a transgenic soybean GTS40-3-2 and endogenous and exogenous gene multi-nested fluorescent quantitative PCR (polymerase chain reaction) detection primer combination method. Multiple PCR, nested PCR and fluorescent quantitative PCR are combined, primer design is strictly controlled, the detection process is improved, a multi-nested fluorescent quantitative PCR detection system is built and can quantitatively detect transgenic soybean GTS40-3-2 strains, common exogenous gene NOS (nitric oxide synthase) terminators, CP4-EPSPS, CaMV35S promoters and soybean endogenous genes Lectin, and sensitivity of the method is improved by one order of magnitude as compared with common fluorescent quantitative PCR. The method has the advantages of small template demand quantity, high sensitivity, high flux, strong specificity and the like, and can be applied to rapidly and quantitatively detecting trans-genes. A novel method is provided for rapidly, accurately and quantitatively detecting the trans-genes at high flux.
Owner:JINAN UNIVERSITY
Method of islet isolation using process control
InactiveUS7045349B2Cell dissociation methodsBioreactor/fermenter combinationsAutomatic controlSeparation technology
Advanced Islet Separation Technology incorporates an automated method, automated control methodology, process control interface, and automated apparatus to separate (isolate) and process pancreatic islets in a tissue suspension in physiologic process solution, utilizing microprocessor controllers and computer control and software programming to interface and control the process temperature, process flowrate, percent hydrogen concentration, dissolved oxygen concentration, endotoxin concentration, dissolved nitric oxide concentration, nitric oxide synthase concentration, proteolytic enzyme activity, and pressure of the islet containing physiologic process solution, including real-time process data acquisition and recording of the process variables.
Owner:BENEDICT DANIEL J +1
3,5 - substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
InactiveUS20090131503A1Diminishment of extentAvoid spreadingBiocideNervous disorderNorepinephrine transporterAdrenergic
The present invention relates to novel 3,5-substituted indole compounds of Formula (I) having nitric oxide synthase (NOS) inhibitory activity together with inhibitory activity at the norepinephrine transporter (NET), to pharmaceutical and diagnostic compositions containing them, and to their medical use.
Owner:NEURAXON INC
Muscle-derived cells (MDCs) for treating muscle- or bone-related injury or dysfunction
The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.
Owner:UNIVERSITY OF PITTSBURGH
Selective Targeting Agents for Mitochondria
InactiveUS20110039792A1Improve survivalOrganic active ingredientsTetrapeptide ingredientsDiseaseRos scavenging
The present invention provides a composition and related methods for delivering cargo to a mitochondria which includes (a) a membrane active peptidyl fragment having a high affinity with the mitochondria and (b) cargo. The cargo may be selected from a wide variety of desired cargos which are to be delivered to the mitochondria for a specific purpose. Compositions and methods are disclosed for treating an illness that is caused or associated with cellular damage or dysfunction which is caused by excessive mitochondrial production of reaction oxygen species (ROS). Compositions which act as mitochondria-selective targeting agents using the structural signaling of the β-turn recognizable by cells as mitochondria) targeting sequences are discussed. Mitochondria and cell death by way of apoptosis is inhibited as a result of the ROS-scavenging activity, thereby increasing the survival rate of the patient. In a preferred embodiment, the compositions and methods may be administered therapeutically in the field to patients with profound hemorrhagic shock so that survival could be prolonged until it is feasible to obtain surgical control of the bleeding vessels. In further preferred embodiments, the composition for scavenging radicals in a mitochondria membrane includes a radical scavenging agent and a membrane active compound having a high affinity with said mitochondrial membrane and associated methods. In another embodiment, the cargo transported by mitochondrial-selective targeting agents may include an inhibitor of nitric oxide synthase (NOS) enzyme activity.
Owner:UNIVERSITY OF PITTSBURGH
Antioxidant and anti-inflammatory activity of compounds and preparations from African nutmeg seeds
The present invention provides methods for reducing the production of nitric oxide, inducible nitric oxide synthase protein and mRNA, and cyclooxygenase-2 protein and mRNA in cells both in vivo and in vitro via the administration of extracts and compounds derived from the seeds of Pycnanthus angolensis Warb. (P. Kombo), commonly known as African nutmeg. These extracts and compounds, namely, kombo butter, kombo butter acid extract, sargaquinoic acid, sargachromenol, and sargahydroquinoic acid, are also useful in the treatment and prevention of a battery of adverse health conditions in human, animal, and avian subjects that are advanced by the production of nitric oxide or its metabolites and / or by the activity of cyclooxygenase-2. Methods for the isolation of kombo butter acid extracts are also provided.
Owner:RUTGERS THE STATE UNIV +1
Camphanylidene and phenylalkyl inositol polyphosphate compounds, compositions, and methods of their use
InactiveUS20070129336A1Avoid absorptionPromote absorptionBiocidePhosphorous compound active ingredientsPolyphosphatePhosphoric acid
Owner:INOLOGIC
Pharmaceutical Composition Comprising Metadoxine and Garlic Oil For Preventing and Treating Alcohol-Induced Fatty Liver and Steatohepatitis
InactiveUS20100062090A1Effective treatmentPrevent hepatitisBiocideOrganic active ingredientsTG - TriglycerideMetadoxine
Provided is a pharmaceutical or food or drink composition for preventing or treating alcohol-induced fatty liver or steatohepatitis comprising metadoxine (pyridoxol 1-2-pyrrolidone-5-carboxylate) and garlic oil as active ingredients. The concurrent administration of metadoxine and garlic oil according to the present invention exhibits outstandingly superior effects of inhibiting the accumulation of triglyceride and increase of blood AST (aspartate aminotransferase) level in liver el tissue, inhibiting the expression of FAS (fatty acid synthase), CYP2E1 and iNOS (inducible nitric oxide synthase) and inhibiting the deactivation of AMPK (AMP-activated protein kinase), as compared to the administration of metadoxine or garlic oil only.
Owner:SEOUL NAT UNIV R&DB FOUND
Pharmaceutical uses of diterpene excavatolide B from a coral or an analogue thereof
The invention relates to use of a diterpene from a coral, excavatolide B, or an analogue thereof for treating a disease associated with inducible nitric oxide synthase, cyclooxygenase-2 and / or matrix metalloproteinase. The invention also relates to use of a diterpene from a coral, excavatolide B, and an analogue thereof for treating a disease associated with TNF-α and / or IL-6 over-expression.
Owner:NAT SUN YAT SEN UNIV
Anti-inflammatory effective component extract of antrodia cinnamomea sporocarp, preparation method and application thereof
The invention discloses an anti-inflammatory effective component extract of antrodia cinnamomea sporocarp, a preparation method and application thereof. The preparation method comprises the following steps of: drying the antrodia cinnamomea sporocarp; and extracting the dried antrodia cinnamomea sporocarp by using ethanol, and collecting an ethanol extract to obtain the anti-inflammatory effective component extract of the antrodia cinnamomea sporocarp. In order to achieve the better extraction effect, the method comprises the following steps of: concentrating the ethanol extract further; layering a concentration product by using water and ethyl acetate; and collecting an ethyl acetate extract to obtain the anti-inflammatory effective component extract. The anti-inflammatory effective component extract of the antrodia cinnamomea sporocarp and Antrocamphin A separated from the antrodia cinnamomea sporocarp can reduce the expression of nitric oxide synthase or cycloxygenase 2 to inhibit pro-inflammation molecules from generating.
Owner:NATIONAL CHUNG HSING UNIVERSITY
Megsin/Rage/Inos-Overexpressing Renal Disease Model Animals and Methods for Evaluating Compounds Using the Model Animals
InactiveUS20080263683A1Evaluating effectHighly accurate experimentsDisease diagnosisOxidoreductasesBiologyKidney
Triple Tg (megsin / RAGE / iNOS-Tg) was created by crossing megsin-Tg with RAGE / iNOS-Tg. The megsin / RAGE / iNOS-Tg develops marked pathologies of diabetic nephropathy unfound in conventional models at early stages, and various pathological conditions such as glomerular hypertrophy were observed uniformly in the megsin / RAGE / iNOS-Tg mice. In addition, it was also found that animals exhibiting these symptoms were useful as a disease model animal for diabetic nephropathy. Specifically, the disease model animals of the present invention overexpress the megsin gene, a gene encoding the receptor for advanced glycation end-products, and an inducible nitric oxide synthase gene. As a result, accompanying kidney function disorders of glomerular failure develop at early stages.
Owner:RENASCI +1
Application of turmeric native
InactiveCN101366709AAvoid damageNervous disorderKetone active ingredientsDiseaseDopamine biosynthesis
The invention discloses novel application of a medicine - curcumin, namely application of the curcumin in preventing and treating or treating the Parkinson disease. After the curcumin acts on an MPTP-constructed Parkinson disease mouse model, the curcumin can effectively promote expression of tyrosine hydroxylase in substantia nigra, lighten damage of sneurotoxin on the tyrosine hydroxylase in substantia nigra, reduces damage of dopaminergic neurons, promote biosynthesis of damaged dopamine and promote restoration and growth of damaged dopaminergic neurons; the curcumin can also inhibit astrocytes to secrete gelatinous fiber proteins, reduce stimulus of the neurotoxin on the astrocytes and lighten phlegmonosis of a brain tissue; moreover, the curcumin can inhibit expression of induction type nitrous oxide synthase, lighten induction of the neurotoxin on the induction type nitrous oxide synthase and inhibit reinforcement of intracephalic oxidative stress reaction. Therefore, the curcumin can effectively reduce damage of the dopaminergic neurons, thereby having significant potential value in developing medicines for preventing and treating and / or treating the Parkinson disease.
Owner:RUIJIN HOSPITAL ATTACHED TO SHANGHAI NO 2 MEDICALUNIV +1
Preparation and application methods of penaeus monodon fermented feed
InactiveCN107114618AImprove immunityImprove survival rateAnimal feeding stuffBacillus licheniformisZoology
The invention relates to preparation and application methods of penaeus monodon fermented feed. The preparation method comprises the following steps: respectively carrying out enlarged culture on bacillus licheniformis, lactobacillus plantarum and candida utilis, then mixing in a volume ratio of 1:1:1, adding brown sugar (2g / 1000mL) and running water into the mixed bacterial solution under the condition that the ratio of the culture solution to water is 1:80, uniformly mixing, uniformly stirring with penaeus monodon compound feed in a ratio of 2:5, sealing with a plastic film, and fermenting for 18-28 hours, so that the fermented feed is obtained. The invention also provides the application method of the fermented feed. The prepared fermented feed is used for feeding penaeus monodon once a day, and the feeding amount is 20-30% of the daily total feeding amount. The prepared fermented feed can obviously improve nitric oxide synthase activity, superoxide dismutase activity, catalase activity, phenoloxidase activity, glutathione peroxidase activity and total antioxidant capacity of penaeus monodon and obviously reduce the malondialdehyde content; and composition of florae in intestines of the penaeus monodon is obviously improved, and the survival rate of penaeus monodon culture is obviously increased.
Owner:TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY
Cyclooxygenase 2 selective inhibitors, compositions and methods of use
InactiveUS7087630B2Unexpected potential for facilitating wound healingImproving cardiovascular profile of COX-BiocideSenses disorderWound healingDisease
The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and / or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and / or nitrosylated, and, optionally, at least one nitric oxide donor, and / or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and / or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and / or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and / or preventing renal and / or respiratory toxicity; for treating and / or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
Owner:NICOX SA
Method of detecting predisposition to high altitude pulmonary edema
The present invention relates to a method for the detection of predisposition to high altitude pulmonary edema (HAPE). It particularly relates to allelic variants of iNOS (inducible nitric oxide synthase) gene, which has been found to be related with the prevalence of HAPE.
Owner:COUNCIL OF SCI & IND RES
Peptoid Agonists of Nerve Growth Factor and Their Use as Medicaments
InactiveUS20120237552A1Preventing and treating nerve cell deathPreventing and treating and damageSenses disorderNervous disorderSide effectHalf-life
Neurotrophin binding to its specific receptors Trk A and p75 leads to the activation of multiple signalling cascades, culminating in neuroprotective and regenerative effects, including neuronal survival and neurite outgrowth. Neurotrophic factors have been used for the treatment of several neurodegenerative diseases. However, their use is limited by their inability to cross the blood-brain barrier, their short half life and their side effects. Small molecule neurotrophin mimetics may be beneficial in treating a number of neurodegenerative disorders. The present invention shows the capacity of nerve growth factor agonist molecules of Formulae I-IV, as defined in the specification, to induce differentiation in PC 12 cells, promote survival in RN22 cells and activate Trk A, IkBa and SAPK / JNK phosphorylation to various extents in both cell lines. In addition these molecules were able to ameliorate acute experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis (MS) animal model, inhibiting brain inflammation and reducing brain damage. We also observed suppression in the production of pro-inflammatory genes like the inducible nitric oxide synthase. These small molecules with NGF agonist activity may be beneficial for MS and other neurodegenerative diseases due to its neuroprotective and immunomodulatory properties.
Owner:MORENO BEATRIZ +4
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com